Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie (prior sponsor, Abbott)
With
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject must be histologically or cytologically diagnosed with advanced or metastatic NSCLC
Subjects must have at least one lesion measurable by CT scan as defined by RECIST
The measurable lesion may have not received radiation therapy
Subject has an Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2
Subject has received at least one prior line of systemic treatment but no more than two treatment regimen(s) for advanced or metastatic NSCLC. In addition, the subject may have received systemic neo-adjuvant or adjuvant chemotherapy for NSCLC
Adequate organ function
You may not be if
Subject has received targeted VEGF/PDGF TKI (tyrosine kinase inhibitor) therapy. Prior Avastin is allowed.
Subject has untreated brain or meningeal metastases.
History of greater than 10% weight loss
Subject has clinically relevant hemoptysis
The subject has proteinuria CTC Grade \> 1
The subject currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure \> 100 mmHg or systolic blood pressure \> 150 mmHg. Subjects may be re-screened if blood pressure is shown to be controlled with or without intervention.
The subject has a documented left ventricular ejection fraction \< 50%
